Fortune
Cover art for Altria sues FDA over nicotine product delays

Altria sues FDA over nicotine product delays

The Marlboro maker says FDA red tape is blocking its nicotine pouches while illegal imports flood the market.

6 cards · 1m 30s · tap to begin

From · · · 1m 30s

Altria sues FDA over nicotine product delays

The Marlboro maker says FDA red tape is blocking its nicotine pouches while illegal imports flood the market.

In brief

The Marlboro maker says FDA red tape is blocking its nicotine pouches while illegal imports flood the market. Altria CEO Sal Mancuso says FDA regulations are slowing the company's nicotine pouch growth and giving illegal competitors an advantage. Originally reported by Fortune.

Altria pivots to nicotine alternatives

Sal Mancuso

Altria Group, which owns Marlboro and Black and Mild, announced its Moving Beyond Smoking initiative in two thousand twenty-three as consumers shift away from cigarettes toward smoke-free alternatives.

On! pouches face regulatory headwinds

CEO Sal Mancuso told Fortune at the Fortune five hundred Innovation Forum in Detroit on Monday that Altria's On! nicotine pouch brand is key to the company, but FDA regulations have slowed its growth.

Mancuso on responsibility and regulation

Mancuso said Altria is the underdog in the pouch category but intends to lead it long term.

“responsibility needs to be at the heart of everything you do”

Altria sues FDA over review delays

Altria, through subsidiaries Helix Innovations and NJOY, sued the FDA in September, claiming the agency blocked newer nicotine products from reaching market through its Premarket Tobacco Product Application review process.

Six months becomes six years

Mancuso said what should take the FDA six months to review was taking six years in some cases, allowing illegal products from China to take market share while skirting safety standards.

Litigation paused, FDA considers changes

U.S. District Judge James Wesley Hendrix of the Northern District of Texas granted a joint request from the FDA and plaintiffs to pause litigation. The FDA said it would consider revisions to the review process.

The big picture

Altria CEO Sal Mancuso says FDA regulations are slowing the company's nicotine pouch growth and giving illegal competitors an advantage.

Read the original on Fortune

Read the TL;DR — this story on one card.

How we make summaries

React

Sign in to react and comment.

Comments (0)

Life is short. Keep it sweet. Respect others' opinions and be kind!

    Recommended next

    More decks on altria and related topics.